Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01467310
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
GSK1120212
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
[object Object]
[object Object]
[object Object]